Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556780 | 0.83 | HSD17B1 (0.59) | CTDSP1CYP1A2CYP2A6HSD17B1HSD17B2 | |
| SCHEMBL2529937 | 0.83 | HSD17B1 (0.59) | CTDSP1CYP1A2CYP2A6HSD17B1HSD17B2 | |
| SCHEMBL29352754 | 0.77 | CTDSP1 (0.63) | CTDSP1CYP1A2HSD17B1HSD17B2GRIN2D | |
| SCHEMBL1458869 | 0.77 | CYP2A6 (0.52) | CYP1A2CYP2A6CA3CA6CA5A | |
| SCHEMBL29616 | 0.77 | CTDSP1 (0.63) | CTDSP1CYP1A2HSD17B1HSD17B2GRIN2D | |
| SCHEMBL29738648 | 0.77 | CTDSP1 (0.63) | CTDSP1CYP1A2HSD17B1HSD17B2GRIN2D | |
| SCHEMBL29857010 | 0.76 | CYP1A2 (0.62) | CTDSP1CYP1A2HSD17B1HSD17B2GRIN2D | |
| SCHEMBL2115683 | 0.76 | CYP1A2 (0.62) | CTDSP1CYP1A2HSD17B1HSD17B2GRIN2D | |
| SCHEMBL12804562 | 0.76 | HSD17B1 (0.56) | CTDSP1CYP1A2HSD17B1HSD17B2GRIN2D | |
| SCHEMBL30704203 | 0.76 | HSD17B1 (0.56) | CTDSP1CYP1A2HSD17B1HSD17B2GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2012131539-A1 | NOVEL BICYCLIC PYRIDINONES | PFIZER INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | PFIZER INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | PFIZER INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | PFIZER INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012131539-A1 | NOVEL BICYCLIC PYRIDINONES | PFIZER INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-1409476-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003006455-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2001017993-A1 | ALKYLPIPERIDI NYLBENZO [D] ISOXAZOLE DERIVATIVES HAVING PSYCHOTROPIC ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS Gyógyszergyár Rt. (HU) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | CTDSP1 2797/4885CYP1A2 195/4885CYP2A6 210/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | CTDSP1 2276/4885CYP1A2 1377/4885CYP2A6 1444/4885 |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CTDSP1 1379/4885CYP1A2 3480/4885CYP2A6 3457/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CTDSP1 3405/4885CYP1A2 4159/4885CYP2A6 3178/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | CTDSP1 3394/4885CYP1A2 1142/4885CYP2A6 702/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | CTDSP1 1895/4885CYP1A2 4428/4885CYP2A6 3321/4885 |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2C19, CYP2D6 | CTDSP1 1204/4885CYP1A2 48/4885CYP2A6 69/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CTDSP1 1379/4885CYP1A2 3480/4885CYP2A6 3457/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CTDSP1 2984/4885CYP1A2 4465/4885CYP2A6 4112/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CTDSP1 2358/4885CYP1A2 3852/4885CYP2A6 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.